Ligandability Assessment of IL-1β by Integrated Hit Identification Approaches.
Anna VulpettiJean-Michel RondeauMarie-Hélène BellanceJutta BlankRalf BoeschAndreas BoettcherFrédéric BornancinSylvia BuhrLauren E ConnorChristoph E DumelinOliver EsserMichael HedigerSamuel HintermannUlrich HommelElke KochGuillaume LapointeLukas LederSylvie LehmannPhilipp LehrPeter MeierLionel MullerDaniela OstermeierPaul RamageSihame Schiebel-HaddadAlexander Baxter SmithAleksandar StojanovicJuraj VelcickyRina YamamotoKonstanze HurthPublished in: Journal of medicinal chemistry (2024)
Human interleukin-1β (IL-1β) is a pro-inflammatory cytokine that plays a critical role in the regulation of the immune response and the development of various inflammatory diseases. In this publication, we disclose our efforts toward the discovery of IL-1β binders that interfere with IL-1β signaling. To this end, several technologies were used in parallel, including fragment-based screening (FBS), DNA-encoded library (DEL) technology, peptide discovery platform (PDP), and virtual screening. The utilization of distinct technologies resulted in the identification of new chemical entities exploiting three different sites on IL-1β, all of them also inhibiting the interaction with the IL-1R1 receptor. Moreover, we identified lysine 103 of IL-1β as a target residue suitable for the development of covalent, low-molecular-weight IL-1β antagonists.